Physician profile
Wade A Brosius
NPI 1043284763
$23,040.77
in general payments reported to CMS, 2019-2025
57 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,725 · 2020: $1,566 · 2021: $5,851 · 2022: $8,849 · 2023: $1,255 · 2024: $2,658 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,301 · Consulting Fee: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,300.63 |
| Consulting Fee | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $11,353.10 | 2021-2022 | |
| Topcon Healthcare, INC. | $1,750.00 | 2024 | |
| Topcon Healthcare Solutions, INC. | $1,250.00 | 2022 | |
| Novo Nordisk INC | $991.30 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $914.54 | 2019-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $849.61 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $708.37 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $520.33 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $484.58 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $456.21 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $332.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $326.15 | 2019-2025 | Belsomra, Enflonsia, Capvaxive |
| Sanofi Pasteur INC. | $278.11 | 2019-2025 | |
| Mannkind Corporation | $263.72 | 2021-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $259.92 | 2019-2023 |
Show all 56 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Brosius listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.